100 related articles for article (PubMed ID: 25736311)
21. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Fornecker LM; Aurran-Schleinitz T; Michallet AS; Cazin B; Guieze R; Dilhuydy MS; Zini JM; Tomowiak C; Lepretre S; Cymbalista F; Brion A; Feugier P; Delmer A; Leblond V; Ysebaert L
Am J Hematol; 2015 Jun; 90(6):511-4. PubMed ID: 25752923
[TBL] [Abstract][Full Text] [Related]
22. A subset of CD45+/CD19 - cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma.
Kim SM; Lee ST; Ryu KJ; Kim HJ; Kim SH; Ko YH; Kim WS; Kim SJ
Leuk Lymphoma; 2015; 56(11):3052-7. PubMed ID: 25739938
[TBL] [Abstract][Full Text] [Related]
23. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
24. Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.
Schreiber S; Hoellein A; Decker T; Jilg S; Dreyling M; Peschel C; Keller U
Leuk Lymphoma; 2015; 56(11):3227-9. PubMed ID: 25754578
[No Abstract] [Full Text] [Related]
25. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
[TBL] [Abstract][Full Text] [Related]
26. Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis.
Fan L; Miao Y; Wu YJ; Wang Y; Guo R; Wang L; Shen AL; Chen YY; Xu W; Li JY
Leuk Lymphoma; 2015; 56(12):3329-35. PubMed ID: 25791119
[TBL] [Abstract][Full Text] [Related]
27. Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma.
Chen Q; Ayer T; Nastoupil LJ; Rose AC; Flowers CR
Value Health; 2015 Mar; 18(2):189-97. PubMed ID: 25773554
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
[No Abstract] [Full Text] [Related]
29. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma.
Xochelli A; Sutton LA; Agathangelidis A; Stalika E; Karypidou M; Marantidou F; Lopez AN; Papadopoulos G; Supikova J; Groenen P; Boudjogra M; Sundstrom C; Ponzoni M; Francova HS; Anagnostopoulos A; Pospisilova S; Papadaki T; Tzovaras D; Ghia P; Pott C; Davi F; Campo E; Rosenquist R; Hadzidimitriou A; Belessi C; Stamatopoulos K
Am J Pathol; 2015 Jun; 185(6):1740-8. PubMed ID: 25843681
[TBL] [Abstract][Full Text] [Related]
30.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.
Gangatharan SA; Maganti M; Kuruvilla JG; Kukreti V; Tiedemann RE; Gospodarowicz MK; Hodgson DC; Sun A; Tsang RW; Pintilie M; Crump M
Br J Haematol; 2015 Aug; 170(3):384-90. PubMed ID: 25904266
[TBL] [Abstract][Full Text] [Related]
32. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
35. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
[TBL] [Abstract][Full Text] [Related]
36. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
37. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.
Brown JR; O'Brien S; Kingsley CD; Eradat H; Pagel JM; Lymp J; Hirata J; Kipps TJ
Blood; 2015 Apr; 125(18):2779-85. PubMed ID: 25769620
[TBL] [Abstract][Full Text] [Related]
38. B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
Zhang W; Wang Y; Wang J; Dong F; Zhu M; Wan W; Li H; Wu F; Yan X; Ke X
Int J Oncol; 2015; 46(6):2562-72. PubMed ID: 25872657
[TBL] [Abstract][Full Text] [Related]
39. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J
Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238
[TBL] [Abstract][Full Text] [Related]
40. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
Samaniego F; Hagemeister F; Romaguera JE; Fanale MA; Pro B; McLaughlin P; Rodriguez MA; Neelapu SS; Fayad L; Younes A; Feng L; Berkova Z; Khashab T; Sehgal L; Vega-Vasquez F; Kwak LW
Br J Haematol; 2015 Jun; 169(6):814-23. PubMed ID: 25828695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
